JP2009543802A - 医学的疾患の治療のためのジアジン及びトリアジン構造を含むｃｘｃｒ４アンタゴニスト - Google Patents

医学的疾患の治療のためのジアジン及びトリアジン構造を含むｃｘｃｒ４アンタゴニスト Download PDF

Info

Publication number
JP2009543802A
JP2009543802A JP2009519653A JP2009519653A JP2009543802A JP 2009543802 A JP2009543802 A JP 2009543802A JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009543802 A JP2009543802 A JP 2009543802A
Authority
JP
Japan
Prior art keywords
compound
acyl
nhr
cxcr4
nrr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543802A5 (enExample
Inventor
リオツタ，デニス・シー
スナイダー，ジエームズ・ピー
チヤン，ウエイチアン
Original Assignee
エモリー・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー・ユニバーシテイ filed Critical エモリー・ユニバーシテイ
Publication of JP2009543802A publication Critical patent/JP2009543802A/ja
Publication of JP2009543802A5 publication Critical patent/JP2009543802A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009519653A 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むｃｘｃｒ４アンタゴニスト Pending JP2009543802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83000606P 2006-07-11 2006-07-11
US81999706P 2006-07-11 2006-07-11
PCT/US2007/073285 WO2008008854A2 (en) 2006-07-11 2007-07-11 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders

Publications (2)

Publication Number Publication Date
JP2009543802A true JP2009543802A (ja) 2009-12-10
JP2009543802A5 JP2009543802A5 (enExample) 2011-09-01

Family

ID=38924159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519653A Pending JP2009543802A (ja) 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むｃｘｃｒ４アンタゴニスト

Country Status (4)

Country Link
US (1) US8080659B2 (enExample)
EP (1) EP2041067A4 (enExample)
JP (1) JP2009543802A (enExample)
WO (1) WO2008008854A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838321A4 (en) * 2005-01-07 2009-03-18 Univ Emory CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION
US8338448B2 (en) 2008-03-28 2012-12-25 Altiris Therapeutics, Inc. Chemokine receptor modulators
US20120294803A1 (en) * 2010-01-27 2012-11-22 Emory University Cxcr4 antagonists for imaging of cancer and inflammatory disorders
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
MX365242B (es) 2011-05-16 2019-05-28 Genzyme Corp El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
WO2013060865A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
ES2634939T3 (es) 2011-11-07 2017-09-29 Emory University Compuestos que contienen aminas tricíclicas para el tratamiento o prevención de síntomas asociados con la disfunción endocrina
EP3296310A1 (en) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
JP6392773B2 (ja) 2012-12-07 2018-09-19 グリコミメティクス， インコーポレイテッド 造血細胞の動員のためにｅ−セレクチンアンタゴニストを使用する化合物、組成物および方法
HUE044571T2 (hu) 2014-06-06 2019-11-28 Univ Muenchen Tech Módosított ciklopentapeptidek és alkalmazásaik
HUE045542T2 (hu) 2014-12-03 2019-12-30 Glycomimetics Inc E-szelektinek és CXCR4 kemokin receptorok heterobifunkcionális inhibitorai
US10434195B2 (en) * 2015-08-03 2019-10-08 Emory University Methylsulfonamide derivatives and uses related thereto
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
WO2018068010A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
JP2022526890A (ja) * 2019-03-22 2022-05-27 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
WO2002002516A2 (en) * 2000-06-30 2002-01-10 Thomas Jefferson University Inhibitors of hiv integrase
JP2002517437A (ja) * 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規なナトリウムチャンネル薬剤および使用
JP2003524620A (ja) * 1999-03-24 2003-08-19 アノーメッド インコーポレイティド ケモカインレセプター結合複素環化合物
WO2005049607A1 (en) * 2003-11-24 2005-06-02 Prometic Biosciences Inc. Triazine dimers for the treatment of autoimmune diseases
WO2005085189A2 (en) * 2004-03-08 2005-09-15 Medical Research Council Analogues of congo red and evaluation of their anti-prion activity
WO2006074426A2 (en) * 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of hiv infection
JP5038905B2 (ja) * 2005-01-07 2012-10-03 エモリー・ユニバーシテイ 医学的障害の治療用のｃｘｃｒ４拮抗薬

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US776465A (en) * 1904-04-15 1904-11-29 Charles A Gildemeyer Spigot.
US5993817A (en) 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
US6358915B1 (en) 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
AU6390696A (en) 1995-06-20 1997-01-22 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, nd their uses
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5922676A (en) 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5874438A (en) 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
US6534626B1 (en) 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2327530A1 (en) 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6420354B1 (en) * 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
EP1050583A4 (en) 1998-11-24 2005-02-02 Hisamitsu Pharmaceutical Co INHIBITORS OF HIV INFECTIONS
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
EP2275447A1 (en) 1999-11-24 2011-01-19 Schering Corporation Methods of inhibiting metastasis
US20030220482A1 (en) 2000-02-03 2003-11-27 Ziwei Huang Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II
AU5811001A (en) 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CN1630517A (zh) 2001-05-24 2005-06-22 吴羽化学工业株式会社 包含含氮化合物的具有cxcr4拮抗作用的药物
WO2003029218A1 (en) 2001-09-28 2003-04-10 Kureha Chemical Industry Company, Limited Novel nitrogenous compound and use thereof
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
US20040132642A1 (en) 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
CA2520406A1 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517437A (ja) * 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規なナトリウムチャンネル薬剤および使用
JP2003524620A (ja) * 1999-03-24 2003-08-19 アノーメッド インコーポレイティド ケモカインレセプター結合複素環化合物
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
WO2002002516A2 (en) * 2000-06-30 2002-01-10 Thomas Jefferson University Inhibitors of hiv integrase
WO2005049607A1 (en) * 2003-11-24 2005-06-02 Prometic Biosciences Inc. Triazine dimers for the treatment of autoimmune diseases
WO2005085189A2 (en) * 2004-03-08 2005-09-15 Medical Research Council Analogues of congo red and evaluation of their anti-prion activity
WO2006074426A2 (en) * 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of hiv infection
JP5038905B2 (ja) * 2005-01-07 2012-10-03 エモリー・ユニバーシテイ 医学的障害の治療用のｃｘｃｒ４拮抗薬

Also Published As

Publication number Publication date
US8080659B2 (en) 2011-12-20
WO2008008854A2 (en) 2008-01-17
EP2041067A4 (en) 2009-11-25
US20090099194A1 (en) 2009-04-16
WO2008008854A9 (en) 2008-03-27
WO2008008854A8 (en) 2009-02-19
WO2008008854A3 (en) 2008-09-25
EP2041067A2 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
JP2009543802A (ja) 医学的疾患の治療のためのジアジン及びトリアジン構造を含むｃｘｃｒ４アンタゴニスト
JP5038905B2 (ja) 医学的障害の治療用のｃｘｃｒ４拮抗薬
WO2008008852A2 (en) Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
US8114884B2 (en) CXCR4 antagonists for the treatment of medical disorders
US8338448B2 (en) Chemokine receptor modulators
US20080227799A1 (en) CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
CN117756789A (zh) 作为选择性Janus激酶抑制剂的氨基吡唑类化合物
EP3108883A1 (en) Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
US10766883B2 (en) Aminopyrazoles as janus kinase inhibitors
CN101137379B (zh) 用于治疗医学病症的cxcr4拮抗剂
HK1156619A (en) Chemokine receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130416